Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Single Ascending Dose and Multiple Ascending Dose Study to Assess Safety, Tolerability, and Pharmacokinetics of Orally Administered ABF- 101

Next Previous
Trial Profile

A Phase 1, Single Ascending Dose and Multiple Ascending Dose Study to Assess Safety, Tolerability, and Pharmacokinetics of Orally Administered ABF- 101

Status: Suspended
Phase of Trial: Phase I

Latest Information Update: 16 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ABF 101 (Primary)
  • Indications Age-related myocardial degeneration; Macular degeneration
  • Focus Adverse reactions
  • Sponsors AptaBio Therapeutics

Most Recent Events

  • 24 Feb 2026 According to AptaBio Therapeutics media release, FDA requested a re-verification of the reliability of the data provided by the facility and has temporarily suspended the clinical trial until the supplementary measures are completed.The company plans to promptly submit supplementary data and normalize clinical trials as soon as possible.
  • 24 Feb 2026 Status changed from recruiting to suspended.
  • 24 Feb 2026 According to AptaBio Therapeutics media release, company announced that it had received a Clinical Hold notice from the U.S. Food and Drug Administration (FDA) regarding the U.S. Phase 1 clinical trial of ABF-101. The primary reason for this clinical hold is administrative and procedural issues at the nonclinical GLP (Good Laboratory Practice) facility, unrelated to drug mechanism or safety issues.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top